Skip to main content

Table 6 univariate and multivariate analysis of progression free survival (PFS)

From: Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

  PFS P-value
  at
12 months (%)
at
24 months (%)
univariate
Analysis
multivariate
Analysis
Age
  ≤ 65 years 50 19   
  > 65 years 67 20 0.925  
Gender
 Female 80 20   
 Male 54 19 0.868  
Karnofsky performance status
  > 80% 65 25   
  ≤ 80% 46 9 0.134  
UICC stage
 III 54 18   
 IV 100 33 0.458  
T category
 1–2 67 0   
 3–4 56 20 0.292  
N category
 0–1 33 0   
 2–3 61 20 0.235  
Histology
 Squamous cell carcinoma 56 19   
 Non- Squamous cell carcinoma 60 20 0.855  
Tobacco consumption (PY)
 0 63 25   
 20–40 38 13   
  > 40 67 20 0.633  
Grading
 Moderately differentiated 50 50   
 Poorly differentiated 59 15   
anaplastic 50 50 0.831  
PD-L1 expression
 0% 86 29   
  ≥ 1% 31 13 0.006 0.061
 CD8+ TILs density     
  ≤ 40% 70 30   
  > 40% 50 17 0.201  
TIME type
 I 100 60   
 II 30 20   
 III 71 14   
 IV 40 0 0.035 0.144